23 Sep 2015
Ergomed shortlisted for Leading Industry Award

Best Contract Research Organisation Finalist for the 2015 Scrip Awards

Guildford, UK – 23 September 2015: Ergomed plc, (LSE: ERGO or ‘Ergomed’) a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announced today that it is has been named as a finalist for the ‘Best CRO’ award at the 11th Annual Scrip Awards 2015. The Awards are judged by a prestigious panel of independent judges alongside the Scrip Intelligence team. The winners will be announced at the dinner to be held at London’s Grosvenor House Hotel on evening of 2nd December.

AIM listed Ergomed has been shortlisted, and is being recognised for its differentiated approach to clinical trials through its co-development business and innovative Study Site Management model. Ergomed also operates a very successful drug safety (pharmacovigilance) business called PrimeVigilance.

Commenting on the nomination,Ergomed’s CEO Dr Miroslav Reljanovic M.D. said: “This is great recognition of Ergomed’s ability and is a further landmark in what has been a successful period for the company following our IPO in 2014. We are very pleased to be a finalist for such a prestigious award. We believe our innovative Study Site Management model and the use of our in-house Study Physician Team are central to our success to date. We are continually looking to develop our clinical research capability to support the development of new drugs. This includes our own investment in drug development through our unique co-development model.”

More information about the Scrip awards, including a full list of the finalists, is available at http://www.scripawards.com/

For further information, please contact:

Hume Brophy

Mary Clark, Supriya Mathur and Hollie Vile

Tel: + 44 203 440 5654


About Ergomed

Ergomed Plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. For further information, visit:https://ergomedplc.com

Forward Looking Statements

Certain statements contained within the announcement are forward looking statements and are based on current expectations, estimates and projections about the potential returns of Ergomed plc (“Ergomed”) and industry and markets in which Ergomed operates, the Directors’ beliefs and assumptions made by the Directors. Words such as “expects”, “anticipates”, “should”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “pipeline” and variations of such words and similar expressions are intended to identify such forward looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate investments and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence, the availability of financing on acceptable terms and changes in the legal or regulatory environment.

These forward-looking statements speak only as of the date of this announcement. Ergomed expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in Ergomed’s expectations with regard thereto, any new information or any change in events, conditions or circumstances on which any such statements are based, unless required to do so by law or any appropriate regulatory authority.